Details of Disease

General Information of Disease (ID: DISVK716)

• Disease Name: Serous cystadenocarcinoma
• Synonyms: serous adenocarcinoma; serous cystadenocarcinoma
• Definition: A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.
• Disease Hierarchy:
  DISYL50L: Serous adenocarcinoma
  :
  DISVK716: Serous cystadenocarcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0024621
  MESH ID: D018284
  UMLS CUI: C0206701
  MedGen ID: 60212
  SNOMED CT ID: 90725004

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MAGEA1	TT63M7Q	Limited	Altered Expression	[1]
EPHB3	TT5LM7U	moderate	Biomarker	[2]
SLC22A16	TTITAVR	moderate	Biomarker	[3]
DDIT4	TTVEOY6	Strong	Altered Expression	[4]
HDAC7	TTMUEK1	Strong	Altered Expression	[5]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ASNS	DEXISVQ	Strong	Biomarker	[6]

This Disease Is Related to 15 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCL25	OTLWJ8CJ	Limited	Altered Expression	[7]
MAGED4B	OTO37U7W	Limited	Altered Expression	[1]
ARAP1	OTINOJJ7	moderate	Biomarker	[8]
GALNT6	OTOQQVH1	moderate	Altered Expression	[9]
PDCD5	OT6T2DDL	moderate	Altered Expression	[10]
PPP2R1A	OTYA3GB4	moderate	Genetic Variation	[11]
BRCA1	OT5BN6VH	Strong	Genetic Variation	[12]
LIMS2	OTZ7IIPM	Strong	Altered Expression	[13]
LIMS3	OTTMS7V8	Strong	Altered Expression	[13]
NEU1	OTH9BY8Y	Strong	Altered Expression	[14]
NEURL1	OT2C4P70	Strong	Altered Expression	[14]
PAX8	OTRPD9MI	Strong	Biomarker	[15]
POLH	OTN07WXU	Strong	Biomarker	[16]
PSD4	OTEFB87Z	Strong	Biomarker	[17]
TNXB	OTVBWAV5	Strong	Biomarker	[18]

References

• [1] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010 Apr 27;10:163.
• [2] EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas.APMIS. 2017 Feb;125(2):122-127. doi: 10.1111/apm.12646.
• [3] Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.Int J Gynecol Pathol. 2007 Jul;26(3):334-40. doi: 10.1097/01.pgp.0000236951.33914.1b.
• [4] Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.Diagn Pathol. 2018 Nov 14;13(1):87. doi: 10.1186/s13000-018-0754-4.
• [5] Association of histone deacetylase expression with histology and prognosis of ovarian cancer.Oncol Lett. 2018 Mar;15(3):3524-3531. doi: 10.3892/ol.2018.7726. Epub 2018 Jan 4.
• [6] Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer.Front Oncol. 2019 Oct 18;9:1072. doi: 10.3389/fonc.2019.01072. eCollection 2019.
• [7] Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
• [8] ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.Acta Oncol. 2020 Jan;59(1):40-47. doi: 10.1080/0284186X.2019.1657941. Epub 2019 Sep 3.
• [9] Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.Anticancer Res. 2017 Jul;37(7):3911-3915. doi: 10.21873/anticanres.11773.
• [10] Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.Oncol Rep. 2011 Feb;25(2):353-8. doi: 10.3892/or.2010.1103. Epub 2010 Dec 13.
• [11] Targeted mutation analysis of endometrial clear cell carcinoma.Histopathology. 2015 Apr;66(5):664-74. doi: 10.1111/his.12581. Epub 2015 Jan 13.
• [12] Retrospective study of a 16year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
• [13] PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.Cytopathology. 2011 Feb;22(1):22-9. doi: 10.1111/j.1365-2303.2010.00757.x.
• [14] Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.Genes Chromosomes Cancer. 2013 Dec;52(12):1178-86. doi: 10.1002/gcc.22113. Epub 2013 Oct 7.
• [15] Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.Hum Pathol. 2018 Feb;72:160-166. doi: 10.1016/j.humpath.2017.10.036. Epub 2017 Dec 11.
• [16] CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.
• [17] Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.Am J Surg Pathol. 2007 Feb;31(2):161-9. doi: 10.1097/01.pas.0000213335.40358.47.
• [18] Tenascin-X is a novel diagnostic marker of malignant mesothelioma.Am J Surg Pathol. 2009 Nov;33(11):1673-82. doi: 10.1097/PAS.0b013e3181b6bde3.